1. Home
  2. Shareholder and Investor Information
  3. RaQualia Receives Approval to List on JASDAQ

Shareholder and Investor Information

NEWS RELEASE
June 16, 2011

RaQualia Receives Approval to List on JASDAQ

June 16, 2011 – RaQualia Pharma Inc. (RaQualia) announced today that it received approval to list its shares on the Osaka Securities Exchange JASDAQ Growth Market. The Company’s common shares are expected to be listed and begin trading on July 20, 2011. RaQualia’s Board of Directors decided on March 14, 2011 to temporarily postpone its planned listing due to the Tohoku-Pacific Ocean Earthquake of March 11 and its impact on the stock market, but the company has continued its preparations since then.

Contact
RaQualia Pharma Inc.
Kazuhiro Ikeda
E-mail: ask@raqualia.com

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics